Skip to main
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics Inc. has demonstrated a strong pre-market performance, with an approximate 22% increase, reflecting investor interest and confidence in the potential of AVTX-009 as an effective therapy for hidradenitis suppurativa (HS). The upcoming LOTUS data readout is anticipated to enhance the understanding of AVTX-009's capabilities, suggesting a positive trajectory for future market expansion in treating inflammatory diseases. The overall market for HS therapies is expected to grow significantly, supported by the development of more active and durable treatment options, which positions Avalo favorably within the biotechnology sector.

Bears say

Avalo Therapeutics's outlook reflects concerns over safety and efficacy, as evidenced by the observation of neutropenia in 4.3% of cases, including severe drops in neutrophil counts. Additionally, the company's competitive position may be compromised by potential efficacy limitations of its treatments, such as lutikizumab, which may experience "target distraction" due to its binding to both IL-1β and IL-1α. Furthermore, the overall low rates of diagnosis and treatment for targeted inflammatory diseases may hinder market growth, suggesting challenges in garnering widespread adoption of Avalo's therapies.

Avalo Therapeutics (AVTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Avalo Therapeutics (AVTX) has a Strong Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.